What Are the Fundamentals Of BIIB?

By Susan Ramirez • Monday, August 07 09:54 • Permanent Link

Biogen logged a -0.1% change during today's morning session, and is now trading at a price of $268.64 per share. The S&P 500 index moved 1.0%. BIIB's trading volume is 208,938 compared to the stock's average volume of 1,124,358.

Biogen trades -21.16% away from its average analyst target price of $340.76 per share. The 29 analysts following the stock have set target prices ranging from $276.0 to $500.0, and on average have given Biogen a rating of buy.

If you are considering an investment in BIIB, you'll want to know the following:

Biogen has moved 23.0% over the last year, and the S&P 500 logged a change of 10.0%
Based on its trailing earnings per share of 20.95, Biogen has a trailing 12 month Price to Earnings (P/E) ratio of 12.8
BIIB has a forward P/E ratio of 16.0 based on its forward 12 month price to earnings (EPS) of $16.83 per share
The company has a price to earnings growth (PEG) ratio of 4.72 — a number near or below 1 signifying that Biogen is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.69
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Based in Cambridge, the company has 8,725 full time employees and a market cap of $38.88 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.